The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 1978-1984

  Rini, Brian I ^a   Campbell, Steven C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

carcinoma; interferon alpha; kidney; neoplasm metastasis; nephrectomy; renal cell

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; BIOLOGICAL ACTIVITY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DECISION MAKING; DISEASE CONTROL; EVOKED RESPONSE AUDIOMETRY; HUMAN; IMMUNOREGULATION; KIDNEY CARCINOMA; MEDLINE; MOLECULAR THERAPY; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; WOUND HEALING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; NEPHRECTOMY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 34248369806     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.136     Document Type: Review

References (50)

1. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655
2. Mickisch G.H., Garin A., van Poppel H., de Prijck L., and Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (2001) 966
3. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071
4. Escudier B., Szczylik C., Eisen T., Stadler W.M., Schwartz B., Shan M., et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23 (2005) 4510
5. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516
6. Bukowski R.M. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19 (2001) 148
7. Wagner J.R., Walther M.M., Linehan W.M., White D.E., Rosenberg S.A., and Yang J.C. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol 162 (1999) 43
8. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994) 85
9. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700
10. Gnarra J.R., Lerman M.I., Zbar B., and Linehan W.M. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22 (1995) 3
11. Hansen W.J., Ohh M., Moslehi J., Kondo K., Kaelin W.G., and Welch W.J. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Molec Cell Biol 22 (2002) 1947
12. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099
13. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505
14. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46 (2003) 1116
15. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327
16. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16
17. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150
18. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096
19. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., and Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999) 2963
20. Gatenby R.A., Gawlinski E.T., Tangen C.M., Flanigan R.C., and Crawford E.D. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res 62 (2002) 5218
21. Alexander J.P., Kudoh S., Melsop K.A., Hamilton T.A., Edinger M.G., Tubbs R.R., et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53 (1993) 1380
22. Seliger B., Hohne A., Knuth A., Bernhard H., Meyer T., Tampe R., et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56 (1996) 1756
23. Kallfelz M., Jung D., Hilmes C., Knuth A., Jaeger E., Huber C., et al. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. Int J Cancer 81 (1999) 125
24. Lahn M., Fisch P., Kohler G., Kunzmann R., Hentrich I., Jesuiter H., et al. Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. Eur Urol 35 (1999) 70
25. Rayman P., Wesa A.K., Richmond A.L., Das T., Biswas K., Raval G., et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 10 (2004) 6360S
26. Wang Q., Redovan C., Tubbs R., Olencki T., Klein E., Kudoh S., et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 61 (1995) 780
27. Kolenko V., Uzzo R.G., Bukowski R., Bander N.H., Novick A.C., Hsi E.D., et al. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 59 (1999) 2838
28. Cardi G., Heaney J.A., Schned A.R., and Ernstoff M.S. Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res 58 (1998) 2078
29. Wu X.X., Mizutani Y., Kakehi Y., Yoshida O., and Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 60 (2000) 2912
30. Finke J.H., Rayman P., George R., Tannenbaum C.S., Kolenko V., Uzzo R., et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. Clin Cancer Res, suppl. 7 (2001) 940s
31. Uzzo R.G., Rayman P., Kolenko V., Clark P.E., Bloom T., Ward A.M., et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 5 (1999) 1219
32. Tatsumi T., Herrem C.J., Olson W.C., Finke J.H., Bukowski R.M., Kinch M.S., et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 63 (2003) 4481
33. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196 (2002) 619
34. Belldegrun A., Shvarts O., and Figlin R.A. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Cancer J Sci Am, suppl. 6 (2000) S88
35. Fujikawa K., Matsui Y., Miura K., Kobayashi T., Oka H., Fukuzawa S., et al. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J Urol 164 (2000) 673
36. Fujikawa K., Matsui Y., Oka H., Fukuzawa S., and Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 162 (1999) 1934
37. Dadian G., Riches P.G., Henderson D.C., Taylor A., Moore J., Atkinson H., et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 74 (1994) 15
38. Dosquet C., Coudert M.C., Lepage E., Cabane J., and Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin Cancer Res 3 (1997) 2451
39. Edgren M., Lennernas B., Larsson A., and Nilsson S. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res 19 (1999) 869
40. Sato K., Tsuchiya N., Sasaki R., Shimoda N., Satoh S., Ogawa O., et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 90 (1999) 874
41. Jacobsen J., Rasmuson T., Grankvist K., and Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163 (2000) 343
42. Slaton J.W., Inoue K., Perrotte P., El-Naggar A.K., Swanson D.A., Fidler I.J., et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158 (2001) 735
43. Yagasaki H., Kawata N., Takimoto Y., and Nemoto N. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 10 (2003) 220
44. Feldman A.L., Alexander Jr. H.R., Yang J.C., Linehan W.M., Eyler R.A., Miller M.S., et al. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95 (2002) 1637
45. Kattan M.W., Reuter V., Motzer R.J., Katz J., and Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (2001) 63
46. Leibovich B.C., Blute M.L., Cheville J.C., Lohse C.M., Frank I., Kwon E.D., et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97 (2003) 1663
47. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454
48. Patard J.J., Kim H.L., Lam J.S., Dorey F.J., Pantuck A.J., Zisman A., et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22 (2004) 3316
49. Kim B., and Louie A.C. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127 (1992) 1343
50. Sherry R.M., Pass H.I., Rosenberg S.A., and Yang J.C. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69 (1992) 1850